The risk may only be noticeable when other blood-thinning supplements are used, when the diet is high in fish, or in those without hypertension
Download the Notable Articles of 2025: nej.md/3L4ot87 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule GLP-1 receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes
Ogilvie P, Thulesen J, Leys C, et al
No cases of pancreatitis or thyroid malignancy were reported during the trial period, though these remain areas of ongoing surveillance given their association with this drug class
Emerging evidence further indicates that MTs particularly MT1 and MT2A constitute a critical cytoplasmic defense layer against cuproptosis by acting as effective copper sponges that sequester excess Cu + and restrict its aberrant interaction with mitochondrial targets 170,173,174
Ulcerative colitis-associated colorectal cancer
